Literature DB >> 16533419

Corticosteroid therapy and chronic obstructive pulmonary disease.

Neil R MacIntyre1.   

Abstract

Chronic obstructive pulmonary disease is characterized in part by a chronic inflammatory state in the airways (largely from chronic noxious stimuli such as tobacco smoke), punctuated with acute inflammatory exacerbations, which are often infectious. Although pathologically and biochemically different from the inflammation of asthma, the chronic inflammation of chronic obstructive pulmonary disease, especially in subgroups with asthma-like features and especially during exacerbations, might be expected to respond to corticosteroid therapy, as does asthma. Complications from long-term corticosteroid use are important, but they appear less when the corticosteroid is given via the inhaled route. Clinical evidence is particularly strong supporting the use of inhaled corticosteroids to prevent exacerbations and oral corticosteroids to reduce the duration and impact of exacerbations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533419

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  3 in total

Review 1.  Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease.

Authors:  Neil MacIntyre; Yuh Chin Huang
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

2.  EMPADE Study: Evaluation of Medical Prescriptions and Adverse Drug Events in COPD Patients Admitted to Intensive Care Unit.

Authors:  Mir S Adil; M Amer Khan; M Nematullah Khan; Ihtisham Sultan; M Aamer Khan; S Amir Ali; Afroze Farooqui
Journal:  J Clin Diagn Res       Date:  2015-11-01

3.  Cistrome-based Cooperation between Airway Epithelial Glucocorticoid Receptor and NF-κB Orchestrates Anti-inflammatory Effects.

Authors:  Vineela Kadiyala; Sarah K Sasse; Mohammed O Altonsy; Reena Berman; Hong W Chu; Tzu L Phang; Anthony N Gerber
Journal:  J Biol Chem       Date:  2016-04-13       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.